Switch to a Completely ONce Daily Regimen Containing Emtricitabine/Tenofovir – Fixed Dose Combination Plus Third QD Partner: 'SONETT'

Trial Profile

Switch to a Completely ONce Daily Regimen Containing Emtricitabine/Tenofovir – Fixed Dose Combination Plus Third QD Partner: 'SONETT'

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2008

At a glance

  • Drugs Antiretrovirals; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SONETT
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 06 Jun 2008 Status changed from in progress to completed.
    • 14 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top